Sentiment Summary
Recent Events
Yuhan Corp is expected to announce its Q1 2026 earnings results around May 18, 2026. Analysts forecast a significant year-over-year increase in operating profit, with FnGuide consensus projecting 31 billion KRW (+384.4% YoY) and NH Investment & Securities forecasting 17.3 billion KRW (+170% YoY). Medium importance is estimated as this growth is likely to impact the price by at least 5%, scheduled.
Ex-dividend date on 2026-05-12 for the final dividend of RMB 0.75 per share for the year ended December 31, 2025. The dividend is scheduled to be paid on June 23, 2026; medium importance is estimated as the dividend payout is a standard positive event for shareholders. scheduled
First quarter 2026 earnings release. Market analysts estimate a price impact of over 1% scheduled.
1Q 2026 earnings release. Analysts forecast operating profit to be in line with market consensus, driven by growth in North America and Europe, offsetting a planned scale-down in China. High importance is estimated due to the anticipated impact of regional strategy shifts, scheduled.
Q1 2026 earnings release scheduled for 2026-04-30. Significant price impact of ≥5% is expected based on historical volatility during earnings periods.
First quarter 2026 earnings release scheduled for April 23, 2026.
Jiangsu Hengrui Pharmaceuticals will hold a board meeting on April 22, 2026, to consider and approve the company's quarterly results for the three months ended March 31, 2026, scheduled. A medium impact is estimated as quarterly results often lead to significant price volatility.
Q1 2026 earnings release for Apr 22, 2026; medium importance estimated due to typical earnings volatility scheduled.
Presentation of new clinical and real-world data for epilepsy drug Cenobamate at the American Academy of Neurology (AAN) annual meeting (Apr 18-22, 2026). Market analysts estimate a price impact of over 1% scheduled.
The company plans to hold its annual general meeting on April 16, 2026, to review the 2025 annual profit distribution plan and elect the new board of directors, scheduled. A low impact is estimated as AGM outcomes are typically aligned with prior announcements.
Celltrion's ADC anti-cancer drug candidate 'CT-P71' to receive U.S. FDA Fast Track designation for urothelial carcinoma on April 9, 2026; this major regulatory milestone is estimated to have a high price impact (≥10%) by accelerating the drug's development and review process, expected.
A competitor, Camurus, filed an international patent for a long-acting formulation of Tirzepatide on April 9, 2026, potentially impacting Peptron's collaboration with Eli Lilly; internal analysis suggests a price impact ≥5% due to increased competitive pressure, expected and estimated.
Received US FDA approval for the Investigational New Drug (IND) application for TQB3205, a Pan-KRAS inhibitor, announced on April 9, 2026; estimated 1-5% impact as IND is an early-stage milestone, expected.
Naldemedine was approved for marketing in the GBA area for treating opioid-induced constipation, announced on April 9, 2026; estimated 1-5% impact due to regional market scope, expected.
Innovent's CDMO business, Altruist Biologics, received a license from China's NMPA on 2026-04-09 for its large-scale production plant in Hangzhou.
Hanwha Corp's board of directors resolved on April 8, 2026, to participate in the paid-in capital increase of its affiliate, Hanwha Solutions, with a planned investment of approximately KRW 844 billion.
Celltrion's biosimilar 'Truxima' expected to be reported as the U.S. market leader with 35.8% share on April 8, 2026; this strong market performance is estimated to have a medium price impact (≥5%) by confirming competitive dominance, expected.
Executive Chairman Shizhong Ding purchased a substantial amount of company shares for approximately HK$239 million, as reported on April 7, 2026, signaling insider confidence; medium impact estimated as significant insider buying typically boosts market sentiment, expected.
Scheduled presentation of updated Phase Ib/II data for Cadonilimab in NSCLC at ELCC 2026 on 2026-04-06; positive clinical progress in major indications typically drives >5% price impact scheduled.